Correlation between real-time heart rate and fatigue in chest compression providers during cardiopulmonary resuscitation: A simulation-based interventional study

Background:The American Heart Association guidelines recommend switching chest compression providers at least every 2 min depending on their fatigue during cardiopulmonary resuscitation (CPR). Although the provider''s heart rate is widely used as an objective indicator for detecting fatigue, the accuracy of this measure is debatable.Objectives:This study was designed to determine whether real-time heart rate is a measure of fatigue in compression providers.Study design:A simulation-based prospective interventional study including 110 participants.Methods:Participants performed chest compressions in pairs for four cycles using advanced cardiovascular life support simulation. Each participant''s heart rate was measured using wearable healthcare devices, and qualitative variables regarding individual compressions were obtained from computerized devices. The primary outcome was correct depth of chest compressions. The main exposure was the change in heart rate, defined as the difference between the participant''s heart rate during individual compressions and that before the simulation was initiated.Results:With a constant compression duration for one cycle, the overall accuracy of compression depth significantly decreased with increasing heart rate. Female participants displayed significantly decreased accuracy of compression depth with increasing heart rate (odds ratio [OR]: 0.97; 95% confidence interval [CI]: 0.95–0.98; P < .001). Conversely, male participants displayed significantly improved accuracy with increasing heart rate (OR: 1.03; 95% CI: 1.02–1.04; P < .001).Conclusion:Increasing heart rate could reflect fatigue in providers performing chest compressions with a constant duration for one cycle. Thus, provider rotation should be considered according to objectively measured fatigue during CPR.     

山东省青岛市城阳区糖尿病患者慢性并发症现状调查

目的对山东省青岛市城阳区糖尿病(DM)患者的慢性并发症现状进行横断面调查。方法对2019年3—12月青岛市城阳区参与“三高共管”项目的8个辖区街道的DM患者进行随机抽样调查,按有无慢性并发症将患者分为2组,对患者的人口学资料、人体测量学等指标进行问卷调查,比较2组DM患者的特点,并对DM慢性并发症的影响因素进行Logistic回归分析。结果本研究共随机抽取DM患者26090例进行调查,其中男12560例,女13530例,有慢性并发症者18950例,无慢性并发症者7140例;肥胖、文化程度低、血糖控制欠佳、遵医嘱行为差、合并基础疾病的DM患者更容易出现并发症。亚组分析表明,女性DM患者的心血管疾病、神经病变和眼科疾病的发生率高于男性,差异有统计学意义(P<0.05或P<0.01);糖化血红蛋白(HbA1c)水平越高,DM病程越长,DM患者的慢性并发症发生率均越高,差异有统计学意义(P<0.05或P<0.01)。患者慢性并发症越多,则人均治疗费用越高,年住院次数越多,住院时间越长,差异有统计学意义(P<0.05或P<0.01)。多因素Logistic回归分析显示,性别、年龄、体质量指数(BMI)、DM病程、HbA1c、空腹血糖(FBG)、低密度脂蛋白(LDL)、尿白蛋白肌酐比值(UACR)、24 h尿蛋白定量、文化程度、规律服药程度、规律测量血糖程度均是DM慢性并发症的影响因素(P<0.05或P<0.01)。结论青岛市城阳区DM患者慢性并发症发生率较高,且影响因素较多,尽早明确危险因素有助于防治DM慢性并发症。     

Bailing Capsule combined with α-ketoacid tablets for stage 3 chronic kidney disease: Protocol of a double-blinded,randomized, controlled trial

Background:Chronic kidney disease (CKD) is a progressive and irreversible loss of kidney function. After stage 3, there will be increased risks of hypertension, heart failure, bone disease, anemia, gastrointestinal symptoms, and progression to end-stage kidney failure without proper intervention and treatment. Compound α-ketoacid tablets (KA) administration plays an important role in clinical CKD adjunctive therapy for patients with restricted protein intake. Bailing Capsule (BC), a commonly used Chinese patent medicine for renal diseases, could regulate human immune function, repair renal tubular epithelial cells, prevent renal tubular atrophy, and reduce kidney damage to improve renal function. In this study, we try to conduct a double-blinded, randomized, controlled trial to observe the efficacy and safety of BC combined with KA in treating patients with stage 3 CKD.Methods:This is a double-blinded, randomized, controlled trial. Patients will be randomly divided into treatment group (BC and KT) and control group (BC-simulation and KT) in a 1:1 ratio according to random number table. The treatment course will be 8 weeks, and the changes of subjective symptoms, patient global assessment (PGA) scale, serum creatinine, cystatin C, and estimated glomerular filtration rate, all related adverse events, vital sign measurements, and physical examinations will be recorded. SPSS 21.0 will be used for data analysis.Conclusions:The results will show whether BC combined with KA could alleviate the symptoms of fatigue, anorexia, halitosis, nausea, itching, and edema, improve kidney function in patients with CKD at stage 3.Trial registration:OSF Registration number: DOI 10.17605/OSF.IO/24AJ7.     

广东省慢性化脓性中耳炎患者耳分泌物的病原体分布及药物敏感性分析

目的分析广东省慢性化脓性中耳炎(CSOM)患者耳分泌物的病原体分布及药物敏感性情况,为临床CSOM的诊断和治疗提供依据。方法回顾性分析2015—2019年1892例确诊为CSOM患者耳分泌物标本的微生物学培养结果,对病原体分布、临床常用抗感染药物的敏感性进行分析。结果共检出1054株条件致病菌,检出率位于前3位的细菌是金黄色葡萄球菌、凝固酶阴性葡萄球菌和铜绿假单胞菌,真菌是近平滑念珠菌、聚多曲霉和黄曲霉。葡萄球菌对红霉素、青霉素G的敏感率较低,对其他常用抗菌药物的敏感率均高于70.0%,铜绿假单胞菌对于常用抗假单胞菌药物的敏感率均高于85.0%。近平滑念珠菌和白色念珠菌对氟康唑、伏立康唑均具有较高的敏感率;黄曲霉、土曲霉对两性霉素B的最小抑菌浓度(MIC)值较高,橘青霉对于伏立康唑的MIC值较高。结论广东省CSOM患者耳分泌物中病原体以葡萄球菌、铜绿假单胞菌、念珠菌和曲霉菌为主;真菌的检出率较其他地区高;检出的病原体对常用的治疗药物具有较高的敏感性。     

Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction

1. Download : Download high-res image (468KB)
2. Download : Download full-size image

     

Identification of 22 novel loci associated with urinary biomarkers of albumin,sodium, and potassium excretion

1. Download high-res image (397KB)
2. Download full-size image

     

益肠通秘汤联合中药热奄包治疗老年脾肾阳虚型慢性便秘效果观察

目的探讨益肠通秘汤联合中药热奄包治疗老年脾肾阳虚型慢性便秘的临床疗效。方法选取2016年4月至2017年1月湖北省中医院肛肠科收治的60例老年脾肾阳虚型慢性便秘患者作为研究对象,并按照随机数表法随机分为试验组(30例)与对照组(30例),其中试验组患者在口服益肠通秘汤的同时采用中药热奄包热敷治疗,对照组患者单纯口服乳果糖口服溶液治疗,对比观察两组患者的腹胀、排便时间、排便顺畅度、便后不尽感等变化情况以及临床疗效与复发情况。结果治疗14 d后,两组患者腹胀、排便时间、排便顺畅度及便后不尽感较治疗前均明显改善,且尤以试验组改善最为显著,两组患者腹胀、排便时间、排便顺畅度及便后不尽感评分分别与治疗前对比,P均0.05,差异具有统计学意义;治疗14 d后,两组患者腹胀及便后不尽感评分对比,P均0.05,差异具有统计学意义;治疗14 d后,两组患者排便时间及排便顺畅度评分对比,P均0.05,差异无统计学意义;治疗14 d后,试验组患者中痊愈17例、显效6例、有效4例、无效3例、总有效率为90. 00%,对照组患者中痊愈9例、显效8例、有效3例、无效10例、总有效率为66.67%,两组对比,P0.05,差异具有统计学意义;治疗后6个月随访,试验组17例痊愈患者中复发4例,对照组9例痊愈患者中复发6例。结论益肠通秘汤联合中药热奄包治疗老年脾肾阳虚型慢性便秘,可有效缓解患者腹胀不适、排便时间延长、排便费力及便后不尽感等临床症状,疗效显著,且复发率较低,值得临床推广应用。     

Modelling human pathology of traumatic brain injury in animal models

Traumatic brain injury (TBI) is caused by a head impact with a force exceeding regular exposure from normal body movement which the brain normally can accommodate. People affected include, but are not restricted to, sport athletes in American football, ice hockey, boxing as well as military personnel. Both single and repetitive exposures may affect the brain acutely and can lead to chronic neurodegenerative changes including chronic traumatic encephalopathy associated with the development of dementia. The changes in the brain following TBI include neuroinflammation, white matter lesions, and axonal damage as well as hyperphosphorylation and aggregation of tau protein. Even though the human brain gross anatomy is different from rodents implicating different energy transfer upon impact, especially rotational forces, animal models of TBI are important tools to investigate the changes that occur upon TBI at molecular and cellular levels. Importantly, such models may help to increase the knowledge of how the pathologies develop, including the spreading of tau pathologies, and how to diagnose the severity of the TBI in the clinic. In addition, animal models are helpful in the development of novel biomarkers and can also be used to test potential disease‐modifying compounds in a preclinical setting.     

Risk factors for newly developed osteoporotic vertebral compression fractures following treatment for osteoporotic vertebral compression fractures

Background context

It has been reported that newly developed osteoporotic vertebral compression fractures (OVCFs) occur at a relatively high frequency after treatment. While there are many reports on possible risk factors, these have not yet been clearly established.